Breaking News, Collaborations & Alliances

Merck, Orion Enter Global Development Pact for Prostate Cancer Drug

Orion’s investigational candidate ODM-208 targets cytochrome P450 11A1 (CYP11A1), an enzyme important in steroid production.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Merck and Orion Corp. entered a global development and commercialization agreement for Orion’s investigational candidate ODM-208 and other drugs targeting cytochrome P450 11A1 (CYP11A1), an enzyme important in steroid production. ODM-208 is an oral, non-steroidal inhibitor of CYP11A1 currently being evaluated in a Phase 2 clinical trial for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC).   Orion and Merck, acting through its subsidiary, Merck Sharp &...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters